Postsurgical gastroparesis syndrome (PGS) following sleeve resection of a giant (6.1 kg) gastric gastrointestinal stromal tumour (GIST)

Tze Hao Leow ¹, Stephen Lam,^{2,3} Loveena Sreedharan,⁴ Bhaskar Kumar³

¹Department of General Surgery, James Paget University Hospitals NHS Foundation Trust, Norwich, UK

²Norwich Medical School, University of East Anglia, Norwich, UK

³Department of Upper Gastrointestinal Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK

⁴Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK

Correspondence to
Dr Tze Hao Leow;
Thleow7@gmail.com

Accepted 16 October 2020

DESCRIPTION

A 70-year-old woman who underwent a recent laparotomy and sleeve resection for a giant gastric gastrointestinal stromal tumour (GIST) presented 2 weeks postoperatively with abdominal distention, vomiting and early satiety.

At the time of initial surgery, 2 months previously, she was found to have a giant mass arising from the greater curvature of the stomach and invading the transverse mesocolon. Her presenting symptoms, at that time, were abdominal distention, postprandial nausea and unintentional weight loss. Due to the extensiveness of the giant mass, it was removed with an open sleeve gastrectomy and transverse colonic resection with primary anastomosis, with the vagus nerve preserved ([figure 1](#)), and a 3-year course of adjuvant imatinib. Postoperative histology reported a 6.1 kg GIST. The patient's other medical history included Bell's palsy, obstructive sleep apnoea and benign uterine fibroids.

Due to the patient's recent surgery, as described above, a CT scan of the abdomen and pelvis with contrast was requested, which showed a massively dilated stomach above the suture line of the previous sleeve resection ([figure 2](#)). The initial concern was that of a benign stricture or narrowing of the gastric sleeve from oedema or early scarring leading to mechanical obstruction. The patient, therefore, underwent an oesophagoduodenoscopy, which showed a grossly dilated stomach filled with food residue. The staple line was intact and there was no suggestion of pyloric obstruction. A barium swallow study was organised, which reported reduced gastric motility and ruled out a mechanical obstruction. These findings were consistent with gastroparesis and a diagnosis of postsurgical gastroparesis syndrome (PGS) was made. A nasojejunal feeding tube of size 8 FR and nasogastric tube

Figure 1 An image captured during open sleeve gastrectomy showing a large mass invading the mesocolon.

Figure 2 Coronal view of an abdominopelvic CT with contrast showing a gross dilatation of the proximal stomach above the suture line measuring 12×18.3 cm (axial)×25.3 cm (coronal) containing food and fluid residue, causing elevation of the left hemidiaphragm.

of size 14 FR were endoscopically placed. Intravenous erythromycin was commenced as a prokinetic agent. However, despite 10 days of conservative measures, her symptoms failed to fully resolve, and a decision to perform a total gastrectomy was made. Complete

Figure 3 Coronal view of an abdominopelvic CT with contrast showing a very large heterogeneous right flank mass measuring 24×13×32 cm with mixed haemorrhagic, cystic and solid components.

© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Leow TH, Lam S, Sreedharan L, et al. *BMJ Case Rep* 2020;**13**:e238267. doi:10.1136/bcr-2020-238267

Images in...

total gastrectomy with a Roux-en-Y reconstruction was performed 4 weeks later and the patient made a full recovery postoperatively. She was seen in the outpatient clinic for a follow-up and had an oncology referral for courses of adjuvant imatinib chemotherapy. Repeated CT scans at 3 months and 6 months later showed no local recurrence or metastatic disease and she remains well.

PGS is defined as delayed gastric emptying in the absence of mechanical gastric outlet obstruction, with the cardinal symptoms of early satiety, postprandial fullness, nausea and vomiting, and bloating after upper gastrointestinal surgery. The reported incidence of PGS after gastric surgery is 0.4%–5%.^{1,2} First-line management of PGS includes correction of fluids, electrolytes, nutrition and glycaemic control in diabetics. Pharmacological management options include prokinetic therapy such as metoclopramide, erythromycin and domperidone with antiemetics to improve symptoms of nausea and vomiting. Gastric electrical stimulation is conditionally used in therapeutic resistant gastroparesis. In the event of failure of medical management, surgical treatments such as completion or subtotal gastrectomy and pyloroplasty may be necessary.³ A study aiming to quantify risk reported that tumour size ≥ 4.75 cm was an independent risk factor of PGS (OR: 2.08, 95% CI: 1.06 to 4.51 for <4.75 cm vs ≥ 4.75 cm).⁴ The suggested hypothesis is that large tumours are more likely to invade the interstitial cells of Cajal, which are responsible for generating electrical activities and propagation of peristaltic contractions.^{5,6} In this case, the patient's tumour measured $24 \times 13 \times 32$ cm and weighed 6.1 kg (figure 3), which increased the risk of developing PGS. As symptoms of PGS can be disabling and prolongs hospitalisation, one must be aware of such complications especially when resecting large gastric tumours such as GISTs, which can grow very large in size.⁷ With giant GISTs, which have been present for several years, one needs to be aware of the risk of gastroparesis as this may influence the type of operation performed. In this case, the GIST was not operable with local wedge resections and an anatomical resection was required. However, one needs to be aware of the risk of having to perform further operative intervention, for example, total gastrectomy in cases of PGS resistant to medical therapy.

Contributors BK, SL and LS: conception and design. THL and SL: acquisition of data and drafting of the study. All authors discussed the planning and conduct of the study, contributed to the analysis and interpretation of the data, and contributed to critical revisions of the study and agreed on the final draft.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iD

Tze Hao Leow <http://orcid.org/0000-0002-2410-888X>

Patient's perspective

The sleeve gastrectomy seemed to have worked at first. Unfortunately, after a couple of months, the bloating and sickness returned. I was admitted and the decision was made to remove my stomach. It has now been just over 8 months since then. I am eating a little more, but sometimes have no appetite for meals. I am not getting as much bloating and sickness. I still have some diarrhoea on some days, but I am able to do more activities and walking for longer now. I feel better in myself.

Learning points

- Postsurgical gastroparesis syndrome (PGS) is a potential postoperative complication in patients who have undergone gastric surgery, which is defined as delayed gastric emptying in the absence of mechanical gastric obstruction with symptoms of early satiety, postprandial fullness, nausea and vomiting, and bloating.
- First-line management of PGS involves correction of fluid status, electrolyte imbalances, nutritional status and glycaemic control in diabetics. Initial conservative management involves prokinetic agents and antiemetics. Surgery may be needed if medical management fails.
- Large tumours involving the stomach such as gastrointestinal stromal tumours (GISTs) are highly likely to invade into the interstitial cells of Cajal. This impairs physiological peristaltic contractions, which subsequently leads to a higher risk of developing PGS.
- With giant GISTs, which have been present for several years, one needs to be aware of the risk of PGS as this may influence the type of operation performed and the risk of needing a further operative intervention.

REFERENCES

- 1 Dong K, Yu XJ, Li B, *et al.* Advances in mechanisms of postsurgical gastroparesis syndrome and its diagnosis and treatment. *Chin J Dig Dis* 2006;7:76–82.
- 2 Meng H, Zhou D, Jiang X, *et al.* Incidence and risk factors for postsurgical gastroparesis syndrome after laparoscopic and open radical gastrectomy. *World J Surg Oncol* 2013;11:144.
- 3 Camilleri M, Parkman HP, Shafi MA, *et al.* Clinical guideline: management of gastroparesis. *Am J Gastroenterol* 2013;108:18–37.
- 4 Chen X-D, Mao C-C, Zhang W-T, *et al.* A quantified risk-scoring system and rating model for postsurgical gastroparesis syndrome in gastric cancer patients. *J Surg Oncol* 2017;116:533–44.
- 5 Zarate N. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. *Gut* 2003;52:966–70.
- 6 Vavricka SR, Greuter T, Gastroparesis GT. Gastroparesis and dumping syndrome: current concepts and management. *J Clin Med* 2019;8:1127.
- 7 Mohamed A, Botros Y, Hanna P, *et al.* Gigantic GIST: a case of the largest gastrointestinal stromal tumor found to date. *Case Rep Surg* 2018;2018:1–5.

Copyright 2020 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <https://www.bmj.com/company/products-services/rights-and-licensing/permissions/>
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow